Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124-I-PET/CT Dosimetry in Differentiated Thyroid Cancer
NCT03841617Phase 2Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2019
- Primary completion
- Nov 2035
- Countries
- 1
01
Overview
Phase 2, open-label trial of Iodine-124 in thyroid cancer (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Comparison of the whole body and lesional 124I uptake at 9 weeks. Started Jul 2019; status: recruiting.
02
Drugs
Iodine-124
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT03841617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841617.